Companies
We are a biotechnology company integrating AI, computation and biological automation to accelerate the design of small molecule and protein therapeutics. Our mission is to decrease the timeline and cost of drug development, while improving the success rate of bring innovative medicines to patients in need. We have two drug discovery engines - ELVIS™ and ROSALYND™ - that enable the design of both small molecule and protein therapeutics, an unmatched capability in the AI drug discovery space. Our therapeutic area-agnostic, end-to-end technology powers the full length of early drug discovery - from novel hit discovery to hit to lead, and lead optimization. We are currently applying our technology to drug discovery programs in several areas including, but not limited to, neuroscience, infectious disease, immunology and oncology.
The next decade is going to see a biotech revolution fueled by three technologies: ability to read DNA (sequencing), ability to write DNA (synthesis), and computational systems that predict what DNA to read and write. With sequencing and synthesis being mainstream now [1], 20n provides the computational systems that predict DNA design for novel industrial biotech and health applications. At 20n, we are taking a fresh look at turning biological data into information. We approach it as a big data learning problem, and bring to bear techniques from machine learning, distributed systems, AI planning, program synthesis, data mining, and natural language processing. With the support of DARPA [2], we are building a team of computer scientists, and bioengineers to look at biology in fundamentally new ways. Our current customers include industrial biotech firms that are leading the charge in transitioning us from traditional unsustainable means of manufacturing to sustainable biological processes leading to advanced fuels, materials, therapeutics, and flavors and fragrances. 20n’s technology helps them enter markets previously thought inaccessible for biology. [1] Sequencing DNA costs $4k/genome (http://www.genome.gov/sequencingcosts/) and is expected to go down to $1k/genome. Synthesizing DNA is at 20cents/bp, and is expected to go down to 0.1cents/bp. [2] DARPA in the past supported work that led to the internet, stealth planes, GPS, and even Douglas Engelbart’s mother-of-all-demos.
The future of medicine is taking shape, but scaling it remains a challenge. Some of the biggest breakthroughs in next generation therapies are being held back by manufacturing constraints. The science is moving fast, but the infrastructure is still catching up. Our VectorSelect platform is designed to unlock the scale these therapies need to survive. We combine massively parallelized screens with computational insights to engineer high yield cell lines and production technologies — accelerating the manufacturing of advanced therapies from the inside out.
7 Cups of Tea is an on-demand emotional health and well-being service. Our bridging technology anonymously & securely connects real people to real listeners in one-on-one chat. Anyone who wants to talk about whatever is on their mind can quickly reach out to a trained, compassionate listener through our network. We have hundreds of listeners who come from all walks of life and have diverse experiences. People connect with listeners on 7 Cups of Tea for all kinds of reasons, from big existential thoughts to small, day-to-day things that we all experience. Unlike talking to family or friends, a 7 Cups of Tea listener doesn’t judge or try to solve problems and say what to do. Our listeners just listen. They understand. They give you the space you need to help you clear your head.
ACX is developing a new standard for precision agriculture technologies by providing sustainable, eco-friendly alternatives to chemical pesticides. Our mission is to transform agriculture through sustainable biological crop protection that increases yields while safeguarding the environment, farmers, and consumers.
Abalone Bio is tackling challenging undrugged targets underlying diseases affecting millions, focusing first cell-specific antibody drugs to treat obesity and metabolic disease without the GI side effects that cause 25% of GLP-1 drug patients to quit after 1 year. + High throughput experimental measurement uniquely leverages AI/ML: We’ve engineered cells to measure antibodies for pharmacological activity, not just structure or binding like others, 100 million at a time, 100X+ the throughput of others. With our large, proprietary activity datasets, we uniquely leverage ML to both unlock the discovery of rare hits and generate optimized hits for challenging targets, starting with G-protein coupled receptors (GPCRs) + Proven success: We have developed antibody agonists (activators) for 2 out of the 8 G-protein coupled receptors ever drugged by biotech. + Pharma traction: We’ve secured 3 partnerships with $3M in revenue and $125M in downstream value. + Externally validated science: We’ve been awarded $7M in non-dilutive grant funding for platform and program development.
Able Health is the one platform physician organizations need to manage value-based programs. From calculating HEDIS and Medicare measures to engaging clinicians and health plans, managing value-based programs can take an army of administrators and IT staff. Able Health simplifies administration, customized to your specific programs, so you can ease today's reporting requirements and set your organization up for the future of healthcare reimbursements.
Non-invasive brain stimulation is a widely-utilized, FDA cleared treatment used for patients diagnosed with depression, but is limited to a hospital setting due to the cost of the device, and complexity of treatment application. Our proprietary brain stimulation device allows patients to be treated directly from their home, with the same efficacy, and at a lower cost of treatment. Currently in FDA pivotal phase for Major Depressive Disorder, and Pilot phase for Alzheimer's and Parkinson diseases.
Adni is the first AI-powered super app for healthcare workers. With Adni, healthcare workers can find jobs, buy gear, trade advice, review education, store credentials, and more. Leading organizations, like Penn Medicine, MedPro, and PRN Healthcare, partner with Adni to recruit empowered healthcare talent faster and cheaper.
We build automation solutions powered by AI to improve the efficiency of diagnostics, documentation, and patient education for dental clinics. Our technology is also used by dental insurance companies to process large volumes of claims by analyzing unstructured data like X-rays, narratives, and documents. We're a dentist and clinic owner, a computer vision expert, and a bioscientist. https://www.adra.ai/
Adventris makes cancer vaccines. Our platform solves the problem of targeting poorly immunogenic oncogenes. Our first "off-the-shelf" vaccine targets KRAS, the most common cancer oncogene. In the long run, we envision a world where every adult receives our pan-cancer vaccines annually – preventing the majority of cancer deaths. If you are interested in learning more about our approach to treat and prevent cancer, please reach out to us at contact@adventris.com
AesculaTech believes in building better lives through smart chemistry. We design custom smart materials for a range of biomedical, commercial, and industrial applications. Our platform technology, AesculaGel offers adaptive response to a wide range of stimuli and can be tailor-made for biocompatibility, material strength, and a range of other attributes. Founded by one of MIT's 35 under 35 Innovators, AesculaTech is the shared vision of scientists, engineers, and medical experts. Our cornerstone product, Humidifeye, is an ophthalmic platform to treat dry eye disease. Dry eye affects more than 25 million Americans and the global treatment market is projected higher than $6 Billion within the next decade. Our thermally responsive, form-fitting materials are suitable for sustained yet reversible occlusion across a range of treatment times. In contrast to existing technologies, our product will not extrude, or cause discomfort as it adapts to patients. Though Humidifeye is not yet FDA approved, expect to hear about it soon! In coordination with partners across several sectors, we have a variety of groundbreaking technologies in the works that live up to our vision. This work has already been recognized. AesculaTech was named a Rosenman Innovator, received a National Science Foundation I-Corps grant, was a finalist in the 2019 Octane High Tech Awards, and is a graduate of both the Y Combinator and TMCx accelerator programs. In short, Y-Combinator was only the beginning.
At AgileMD, we are building the most advanced real-time predictive analytics and clinical algorithms platform for hospitals. Our cloud-based engine helps thousands of doctors and nurses around the country make medical decisions, so that every patient receives the highest quality and value of care based on the latest medical knowledge and data.
Aidy is a mobile app that helps people live fuller lives with chronic health conditions, beginning with Inflammatory Bowel Disease (Crohn’s Disease and Ulcerative Colitis). Our app lets users easily log their symptoms, diet, and treatments, then uses clinical indices to track disease severity and trends over time. Aidy excels at identifying patterns between diet, treatment adherence, and symptoms, giving our users a much more comprehensive and up-to-date picture of their condition to supplement clinician care. Previously in our careers, both Max and Peter worked in health in different capacities. At the Rockefeller Foundation and the United States Senate, Max worked in public health policy and COVID-19 response, while Peter worked as an ML researcher for a number of biotech companies. After a lengthy “pivot hell” we decided to finally listen to a friend with IBD who insisted that there weren’t any decent apps to help people live with the disease. Pretty quickly, we discovered how LLMs and regular structured questionnaire responses could provide a level of patient empowerment not possible before for chronic diseases. From there, Aidy was (re)born!
Airo Health is a fast growing Y Combinator-funded company building a next generation armband that has changed people think about their health. We are a multidisciplinary team that brings together expertise in biomedical engineering, user experience, artificial intelligence, software engineering, hardware engineering, and manufacturing. Mental Health, an issue often neglected, directly affects your overall health, quality of life, and productivity. Airo is your companion through the stressful times. It sits on your arm and automatically tracks when you’re getting anxious and recommends easy tweaks that reduce stress.
For the first time in history, technology exists to create a healthcare system that anticipates your needs, responds with precision and is accessible to everyone -- regardless of financial means or geography. Since 2015, Akido Labs singular focus has been to make this vision a reality.
Akute Health makes an electronic medical record (EMR) system & digital infrastructure tools used by digital health companies to track patients. Our EMR is a web app used daily by clinical teams at digital health companies similar to WeightWatchers, Ro, Hims, and One Medical. In 2015, I was diagnosed with cancer and spent 9 months in the hospital. While in the hospital, I built an app to track my own records. I needed something that was simple to use and allowed me to easily track & trend different types of data. I later turned that app into a full medical record system. We now have hundreds of customers and over 50k active patient records. We are building the de facto EMR for digital health companies.
AlemHealth connects hospitals and diagnostic centres in emerging markets to a global network of diagnostic imaging services. Our suite of plug-and-play radiology solutions makes it easy for any facility anywhere to access and provide world-class diagnostic care to its patients. We designed our hardware and software from the ground up specifically for emerging markets, where access to internet, electricity, and clinicians can be difficult. Learn more about our solutions at www.alemhealth.com.
At Alfie, we've built a rigorous virtual medical program based on the top research from Cleveland Clinic and Harvard that allows us to precisely determine which weight loss regimen and (as needed) medications will be most effective for our members in a multimodal approach. We're optimizing exercise/nutrition/medications in complex care pathways like no one else has before. Our program has been shown to be 2x more effective than standard prescription medication and 5x more effective than habit change alone. We've raised capital from Goodwater Capital, Nina Capital, Air Force Ventures, and Phoenix Club, and various super angels including the founder of OpenTrons (medical labs automation; have raised $240 mill). Also, we're a Y Combinator graduate.